EP 4142702 A1 20230308 - E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS
Title (en)
E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS
Title (de)
E-PROTEIN-KANALBLOCKER UND ORF3-INHIBITOREN ALS ANTI-COVID-19-MITTEL
Title (fr)
INHIBITEURS DE CANAL DE PROTÉINE E ET INHIBITEURS DE L'ORF3 UTILISÉS EN TANT QU'AGENTS ANTI-COVID-19
Publication
Application
Priority
- US 202063018598 P 20200501
- US 202063117619 P 20201124
- IL 2021050501 W 20210502
Abstract (en)
[origin: WO2021220284A1] Pharmaceutical compositions comprising a SARS-CoV-2 E protein channel blocker and ORF3 inhibitors for treating or preventing SARS-CoV-2 virulence in a subject, are provided. Further provides is a pharmaceutical composition comprising a SARS-CoV-2 E protein channel blocker or an ORF3 inhibitor for preventing SARS-CoV-2 cell entry, uncoating and/or release from a cell.
IPC 8 full level
A61K 31/13 (2006.01); A61K 31/155 (2006.01); A61K 31/357 (2006.01); A61K 31/375 (2006.01); A61K 31/40 (2006.01); A61K 31/433 (2006.01); A61K 31/4427 (2006.01); A61K 31/495 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/64 (2006.01); A61K 31/704 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01)
CPC (source: EP IL)
A61K 31/13 (2013.01 - EP IL); A61K 31/155 (2013.01 - EP IL); A61K 31/357 (2013.01 - EP IL); A61K 31/375 (2013.01 - EP IL); A61K 31/40 (2013.01 - EP IL); A61K 31/433 (2013.01 - EP IL); A61K 31/4427 (2013.01 - EP IL); A61K 31/495 (2013.01 - EP IL); A61K 31/506 (2013.01 - EP IL); A61K 31/517 (2013.01 - EP IL); A61K 31/64 (2013.01 - EP IL); A61K 31/704 (2013.01 - EP IL); A61K 31/7072 (2013.01 - EP IL); A61K 31/7076 (2013.01 - EP IL); A61K 31/708 (2013.01 - EP IL); A61K 45/06 (2013.01 - EP IL); A61P 31/14 (2017.12 - EP IL)
Citation (search report)
See references of WO 2021220284A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021220284 A1 20211104; AU 2021265602 A1 20230119; BR 112022022243 A2 20221220; CA 3177537 A1 20211104; CN 115867265 A 20230328; EP 4142702 A1 20230308; IL 297852 A 20230101; JP 2023524522 A 20230612; KR 20230035524 A 20230314; MX 2022013744 A 20230124
DOCDB simple family (application)
IL 2021050501 W 20210502; AU 2021265602 A 20210502; BR 112022022243 A 20210502; CA 3177537 A 20210502; CN 202180046512 A 20210502; EP 21731597 A 20210502; IL 29785222 A 20221101; JP 2022566682 A 20210502; KR 20227042356 A 20210502; MX 2022013744 A 20210502